Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06444399
Status:
RECRUITING
Last Update Posted:
2024-06-05
First Post:
2024-05-31
Brief Title:
Deucravacitinib BMS-986165 for Pityriasis Rubra Pilaris
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Deucravacitinib BMS-986165 in the Treatment of Pityriasis Rubra Pilaris
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib BMS-986165 in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment IGA PASI- 50 75 90 DLQI NRS itch and Skindex-16 at week 24 To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None